2011

Nedelkova, M., Maresca, M., Fu, J., Rostovskaya, M., Chenna, R., Thiede, C., Anastassiadis, K., Sarov, M. & Stewart, A.F. (2011) Targeted isolation of cloned genomic regions by recombineering for haplotype phasing and isogenic targeting. Nucleic Acids Res, 39, e137.

Ovcharenko, D., Stolzel, F., Poitz, D., Fierro, F., Schaich, M., Neubauer, A., Kelnar, K., Davison, T., Muller-Tidow, C., Thiede, C., Bornhauser, M., Ehninger, G., Brown, D. & Illmer, T. (2011) miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol, 39, 1030-1042 e1037.

Sockel, K., Wermke, M., Radke, J., Kiani, A., Schaich, M., Bornhauser, M., Ehninger, G., Thiede, C. & Platzbecker, U. (2011) Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica, 96, 1568-1570.

Schneider, F., Hoster, E., Schneider, S., Dufour, A., Benthaus, T., Kakadia, P.M., Bohlander, S.K., Braess, J., Heinecke, A., Sauerland, M.C., Berdel, W.E., Buechner, T., Woermann, B.J., Feuring-Buske, M., Buske, C., Creutzig, U., Thiede, C., Zwaan, M.C., van den Heuvel-Eibrink, M.M., Reinhardt, D., Hiddemann, W. & Spiekermann, K. (2012) Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol, 91, 9-18.

Damm, F., Thol, F., Hollink, I., Zimmermann, M., Reinhardt, K., van den Heuvel-Eibrink, M.M., Zwaan, C.M., de Haas, V., Creutzig, U., Klusmann, J.H., Krauter, J., Heuser, M., Ganser, A., Reinhardt, D. & Thiede, C. (2011) Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia, 25, 1704-1710.
Taube, F., Stolzel, F., Thiede, C., Ehninger, G., Laniado, M. & Schaich, M. (2011) Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone? Haematologica, 96, e31.

Rollig, C., Bornhauser, M., Thiede, C., Taube, F., Kramer, M., Mohr, B., Aulitzky, W., Bodenstein, H., Tischler, H.J., Stuhlmann, R., Schuler, U., Stolzel, F., von Bonin, M., Wandt, H., Schafer-Eckart, K., Schaich, M. & Ehninger, G. (2011) Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol, 29, 2758-2765.
Schaich, M., Rollig, C., Soucek, S., Kramer, M., Thiede, C., Mohr, B., Oelschlaegel, U., Schmitz, N., Stuhlmann, R., Wandt, H., Schafer-Eckart, K., Aulitzky, W., Kaufmann, M., Bodenstein, H., Tischler, J., Ho, A., Kramer, A., Bornhauser, M., Schetelig, J. & Ehninger, G. (2011) Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol, 29, 2696-2702.

Bornhauser, M., Thiede, C., Platzbecker, U., Kiani, A., Oelschlaegel, U., Babatz, J., Lehmann, D., Holig, K., Radke, J., Tuve, S., Wermke, M., Wehner, R., Jahnisch, H., Bachmann, M.P., Rieber, E.P., Schetelig, J., Ehninger, G. & Schmitz, M. (2011) Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood, 117, 7174-7184.
Oelschlaegel, U., Mohr, B., Schaich, M., Kroschinsky, F., Parmentier, S., Bornhauser, M., Ehninger, G. & Thiede, C. (2011) Reply to: 'Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity' by Kern et al. Leukemia, 25, 895-897.

Tuve, S., Gayoso, J., Scheid, C., Radke, J., Kiani, A., Serrano, D., Platzbecker, U., Rodriguez-Macias, G., Wermke, M., Holtick, U., Balsalobre, P., Middeke, J.M., Shayegi, N., Chemnitz, J.M., Krause, A., Gruner, N., Fussel, M., Schetelig, J., Thiede, C., Ehninger, G., Hallek, M., Diez-Martin, J.L. & Bornhauser, M. (2011) Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy. Leukemia, 25, 880-883.

Tickenbrock, L., Klein, H.U., Trento, C., Hascher, A., Gollner, S., Baumer, N., Kuss, R., Agrawal, S., Bug, G., Serve, H., Thiede, C., Ehninger, G., Stadt, U.Z., McClelland, M., Wang, Y., Becker, A., Koschmieder, S., Berdel, W.E., Dugas, M. & Muller-Tidow, C. (2011) Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival. Leuk Res, 35, 620-625.
Stolzel, F., Pfirrmann, M., Aulitzky, W.E., Kaufmann, M., Bodenstein, H., Bornhauser, M., Rollig, C., Kramer, M., Mohr, B., Oelschlagel, U., Schmitz, N., Soucek, S., Thiede, C., Ehninger, G. & Schaich, M. (2011) Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia, 25, 420-428.